睾酮替代治疗期间的前列腺风险与监测
性腺功能减退男性前列腺癌死亡风险较低,但睾酮治疗是否增加前列腺安全事件风险仍有争议。包括睾酮试验、TEAAM试验、糖尿病睾酮试验和TRAVERSE试验在内的多项研究对男性给予睾酮或安慰剂治疗至少1年,并前瞻性收集前列腺安全数据。在排除前列腺癌高风险男性后,睾酮组与安慰剂组的高级别或任何前列腺癌、急性尿潴留、良性前列腺增生手术、前列腺活检或下尿路症状新药物治疗的发生率均较低且无差异;睾酮未加重下尿路症状,但治疗第一年睾酮组前列腺特异性抗原升高幅度大于安慰剂组。
要点
- 在排除前列腺癌高风险的性腺功能减退男性中,睾酮替代治疗的前列腺不良事件风险较低。
- 睾酮组与安慰剂组的高级别或任何前列腺癌、急性尿潴留、良性前列腺增生手术、前列腺活检或下尿路症状新药物治疗发生率无差异。
- 睾酮治疗第一年前列腺特异性抗原升高幅度大于安慰剂组,但未加重下尿路症状。
核心结论
- 对排除前列腺癌高风险的性腺功能减退男性,睾酮治疗与前列腺不良事件低风险相关。
- 基线评估前列腺癌风险并采用标准化监测计划可减少不必要的前列腺活检,同时有助于发现接受睾酮替代治疗男性的高级别前列腺癌。
研究设计与样本
- 多项研究(包括4项较大规模随机试验:睾酮试验、TEAAM试验、糖尿病睾酮试验和TRAVERSE试验)对性腺功能减退男性给予睾酮或安慰剂治疗至少1年,并前瞻性收集前列腺安全数据。
- TRAVERSE试验因样本量较大、持续时间较长且对前列腺事件进行裁定,提供了睾酮替代治疗期间前列腺不良事件风险的全面数据。
主要发现
- 在排除前列腺癌高风险的性腺功能减退男性中,高级别或任何前列腺癌、急性尿潴留、良性前列腺增生手术、前列腺活检或下尿路症状新药物治疗的发生率均较低,且睾酮组与安慰剂组之间无差异。
- 睾酮未加重下尿路症状。
- 睾酮替代治疗第一年,睾酮组前列腺特异性抗原升高幅度大于安慰剂组。
临床怎么用
- 对接受睾酮替代治疗的性腺功能减退男性,应进行基线前列腺癌风险评估并采用标准化监测计划,以减少不必要的前列腺活检并有助于发现高级别前列腺癌。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT: Men with hypogonadism have reduced risk of prostate cancer mortality; whether testosterone treatment increases the risk of prostate safety events in men with hypogonadism remains controversial. Several studies including 4 larger randomized trials-the Testosterone Trials, TEstosterone and Atherosclerosis Progression in Aging Men (TEAAM) trial, Testosterone for Diabetes Mellitus trial, and Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) trial-treated men with testosterone or placebo for 1 year or longer and reported prospectively ascertained prostate safety data. The TRAVERSE Trial, because of its large size, longer duration, and adjudication of prostate events, has provided comprehensive data on the risk of adverse prostate events during testosterone replacement therapy (TRT). Among men with hypogonadism, carefully screened to exclude those at high risk of prostate cancer, the incidences of high-grade or any prostate cancer, acute urinary retention, surgical procedure for benign prostatic hyperplasia, prostate biopsy, or new pharmacologic therapy for lower urinary tract symptoms were low and did not differ between the testosterone and placebo groups. Testosterone did not worsen lower urinary tract symptoms. TRT was associated with a greater increase in prostate-specific antigen than placebo in the first year of treatment. CONCLUSION: Testosterone treatment of men with hypogonadism, screened to exclude those at high risk of prostate cancer, is associated with low risk of adverse prostate events. Baseline evaluation of prostate cancer risk and a standardized monitoring plan can minimize the risk of unnecessary prostate biopsy while enabling the detection of high-grade prostate cancers in men receiving TRT.
引用
- Bhasin S, Thompson IM. Prostate Risk and Monitoring During Testosterone Replacement Therapy. J Clin Endocrinol Metab. 2024. PMID: 38753865. doi:10.1210/clinem/dgae334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。